Trial Profile
Chemotherapy in KRAS mutated chemotherapy naive non-small cell lung cancer patients: a phase III study comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Dec 2021 Planned End Date changed from 1 Apr 2021 to 1 Apr 2024.
- 06 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 27 Aug 2020 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.